Raloxifene Hydrochloride is Used for preventing and treating osteoporosis in postmenopausal women and inhibiting bone resorption, as well as for preventing breast cancer. It was first introduced by Eli Lilly And Co in its drug Evista on Dec 9, 1997. 9 different companies have introduced drugs containing Raloxifene Hydrochloride.

Raloxifene Hydrochloride Patents

Given below is the list of patents protecting Raloxifene Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Evista	US6458811	Benzothiophenes formulations containing same and methods	Mar 10, 2017 (Expired)	Lilly
Evista	US6797719	Benzothiophenes, formulations containing same, and methods	Mar 10, 2017 (Expired)	Lilly
Evista	US6894064	Benzothiophenes, formulations containing same, and methods	Mar 10, 2017 (Expired)	Lilly
Evista	US8030330	Benzothiophenes, formulations containing same, and methods	Mar 10, 2017 (Expired)	Lilly
Evista	US5478847	Methods of use for inhibiting bone loss and lowering serum cholesterol	Mar 02, 2014 (Expired)	Lilly
Evista	US5811120	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation	Mar 02, 2014 (Expired)	Lilly
Evista	US5972383	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation	Mar 02, 2014 (Expired)	Lilly
Evista	USRE39050	Methods of use for inhibiting bone loss and lowering serum cholesterol	Mar 02, 2014 (Expired)	Lilly
Evista	US5393763	Methods for inhibiting bone loss	Jul 28, 2012 (Expired)	Lilly
Evista	US5457117	Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride	Jul 28, 2012 (Expired)	Lilly
Evista	US6906086	Methods for inhibiting bone loss	Jul 28, 2012 (Expired)	Lilly
Evista	USRE38968	Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride	Jul 28, 2012 (Expired)	Lilly
Evista	USRE39049	Methods for inhibiting bone loss	Jul 28, 2012 (Expired)	Lilly

Add above patents to watchlist

Raloxifene Hydrochloride's Family Patents

Full family tree

Raloxifene Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Raloxifene Hydrochloride. The first generic version for Raloxifene Hydrochloride was by Teva Pharmaceuticals Usa and was approved on Mar 4, 2014. And the latest generic version is by Cadila Pharmaceuticals Ltd and was approved on Aug 18, 2020.

Given below is the list of companies who have filed for Raloxifene Hydrochloride generic, along with the locations of their manufacturing plants worldwide.